NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said on Monday that the investment ...

The acquisition is intended to expand the French firm's presence in sequencing-based infectious disease testing.

Last week, readers were most interested in a story about reports of a possible sale by Thermo Fisher Scientific of parts of its diagnostics business.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

The RiskReveal assay was used to determine which early-stage non-squamous NSCLC patients should undergo adjuvant chemotherapy ...

The Birmingham, UK, firm hopes to develop a broader test menu with industry partners, using AI and machine-learning approaches.

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

The University of Chicago spinout said that it will use the money to support the commercialization of its saliva-based sequencing test for oral cancers.

NEW YORK — Gut microbiome health startup 32 Biosciences said on Tuesday that it has raised $6 million in private funding, which it said will support the development of its first products.

The agency granted clearances for tests for cancer and precancer disorders, infectious respiratory diseases, and risk of sepsis and septic shock, among others.

Last week, readers were most interested in a story about the FDA's decision not to appeal a court decision vacating the agency's LDT rule.